A cluster-randomized trial of the school-based 'Superprotegidas' behavioral intervention to improve HPV vaccination uptake in Colombian girls.

VaccineSep 17, 2026 (epub)
Clinical ResearchPediatricsPreventive Medicine / Public Health

Veronica Cordoba-Sanchez, Mariantonia Lemos, Ana Milena Gaviria-Gómez et al.

✦ AI-curated · Sources linked

In 30 seconds

This cluster-randomized trial assessed the 'Superprotegidas' behavioral intervention aimed at increasing HPV vaccination rates among Colombian girls aged 9-14. The study found that post-intervention vaccination rates were significantly higher in the intervention group (52.4%) compared to the control group (28.6%), with an odds ratio of 2.75 (95% CI: 1.06-7.12).

Key findings

  • Post-intervention vaccination rates were 52.4% in the intervention group versus 28.6% in the control group.
  • The odds ratio for vaccination in the intervention group was 2.75 (95% CI: 1.06-7.12).
  • Predictors of vaccination included lower school level and higher behavioral driver scores.
  • Higher caregiver self-efficacy was also associated with increased vaccination rates.

Why it matters

Increasing HPV vaccination rates is crucial for preventing cervical cancer. This study demonstrates that school-based behavioral interventions can effectively enhance vaccination uptake among young girls and their caregivers.

Source

PubMed · PMID 42753387

Published in Vaccine. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.